Enanta Pharmaceuticals (ENTA) Depreciation & Amortization (CF) (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Depreciation & Amortization (CF) data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) changed 0.5% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.9 million (up 55.86% YoY) and the FY2025 annual result came in at $4.6 million, up 96.32% from the prior year.
• Depreciation & Amortization (CF) declined to $1.2 million in Q1 2026, from $1.2 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.3 million in Q3 2025 to a low of $479000.0 in Q3 2024.
• A 5-year average of $819117.6 and a median of $669000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) sank 34.49% — and 2025, when it jumped 168.06%.
• Tracing ENTA's Depreciation & Amortization (CF) over 5 years: stood at $511000.0 in 2022, then gained by 25.64% to $642000.0 in 2023, then surged by 38.47% to $889000.0 in 2024, then soared by 38.36% to $1.2 million in 2025, then fell by 1.71% to $1.2 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.2 million (Q1 2026), $1.2 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.